Categories: News

Delivra Health Brands Announces Adoption of a New Fixed Share Option Plan

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Vancouver, British Columbia–(Newsfile Corp. – March 20, 2024) – Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) (“Delivra Health” or the “Company“), a consumer packaged goods company uniquely positioned in the health and wellness sector, announced today that its Board of Directors has adopted a new 10% fixed stock option plan (the “Stock Option Plan“), which has been approved by the TSX Venture Exchange (“TSXV“). The Stock Option Plan replaces the Company’s previous 10% fixed stock option plan, announced on July 14, 2020 (the “Predecessor Plan“).

Under the Stock Option Plan, the Company may grant options to acquire up to 31,261,785 common shares of the Company, representing 10% of the Company’s current issued and outstanding common shares, subject to the terms and conditions prescribed by the TSXV, and applicable securities laws. Any options outstanding under the previous stock option plan will be governed by the new Stock Option Plan.

About Delivra Health Brands Inc.

Helping people take control of their health with alternative wellness solutions is what energizes the Delivra Health team! The Delivra Health portfolio features innovative brands like Dream Water® and LivRelief™, which deliver relief from common everyday issues like chronic pain, anxiety, and sleeplessness. Delivra Health products have allowed millions of customers to reclaim their mobility, energy, and in turn, quality of life. The websites of the Company’s two subsidiaries are  Dream Water® and  LivReliefTM. For more information, please visit  www.delivrahealthbrands.com.

Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.

Investor Relations:
Jack Tasse
Chief Financial Officer
IR@delivrahealth.com
1-877-915-7934

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/202453

Staff

Recent Posts

Hemostemix Closes $469,366 Private Placement

Calgary, Alberta--(Newsfile Corp. - July 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE:…

46 minutes ago

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions Distinguished experts Dr.…

47 minutes ago

Virbac : Declaration of the number of shares and voting rights 06/2025

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of…

47 minutes ago

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC…

47 minutes ago

Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner

The expert jury selected Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D. of…

47 minutes ago